Dr. Lal PathLabs (LALPATHLAB) investor relations material

Executive summary

• Achieved highest quarterly revenue growth in four years, driven by strong patient and sample volume increases and operational momentum in Q1 FY27, with a focus on execution, scaling, and rural market expansion.

• Launched a rural outreach program active in seven states, testing over 110,000 patients in Q1 FY27.

• Incorporated a wholly owned subsidiary in Dubai, expanding international presence beyond Nepal and Bangladesh; operations yet to commence.

• Continued investment in scientific leadership, R&D, digital infrastructure, and service standards, including introduction of advanced diagnostic tests and GenAI patient bot.

• Approved unaudited standalone and consolidated financial results for the quarter ended June 30, 2026.

Financial highlights

• Q1 FY27 consolidated revenue at INR 7,977 million (₹798 crore), up 19.1% year-over-year from INR 6,698 million (₹670 crore).

• EBITDA grew 28.7% to INR 247 crore, with a margin of 31%.

• Profit after tax increased 27.2% to INR 170 crore, PAT margin at 21.4%.

• Earnings per share at INR 10.1, up 27.8% year-over-year; consolidated basic EPS for Q1 FY27: INR 10.15.

• Net cash and equivalents stood at INR 1,693 crore as of June 30, 2026.

Outlook and guidance

• Targeting sustainable revenue growth, supported by volume tailwinds, expanding footprint, and ongoing investments in scientific leadership and digital transformation.

• Guidance for mid-teen revenue growth and 27%-28% EBITDA margin maintained, with potential for upward revision after H1.

• Interim dividend of INR 5 per share declared; final dividend of INR 4 per share proposed for FY26, subject to approval.

• Price increases to be considered after H1, with CGHS price hike benefit expected for 2-3 more quarters.